Details for Patent: 11,234,976
✉ Email this page to a colleague
Which drugs does patent 11,234,976 protect, and when does it expire?
Patent 11,234,976 protects PYRUKYND and is included in one NDA.
This patent has twenty-five patent family members in nineteen countries.
Summary for Patent: 11,234,976
| Title: | Methods of using pyruvate kinase activators |
| Abstract: | Described herein are methods for using compounds that activate pyruvate kinase. |
| Inventor(s): | Agresta; Samuel V. (Lexington, MA), Chen; Yue (Quincy, MA), Cohen; Marvin B. (Newtown, PA), Dang; Lenny (Boston, MA), Kung; Charles (Arlington, MA), Merica; Elizabeth A. (Boston, MA), Silver; Bruce A. (Dunkirk, MD), Yang; Hua (Acton, MA) |
| Assignee: | Agios Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 15/735,036 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,234,976
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-001 | Feb 17, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG | ⤷ Sign Up | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-002 | Feb 17, 2022 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG | ⤷ Sign Up | ||||
| Agios Pharms Inc | PYRUKYND | mitapivat sulfate | TABLET;ORAL | 216196-003 | Feb 17, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,234,976
| PCT Information | |||
| PCT Filed | June 10, 2016 | PCT Application Number: | PCT/US2016/036893 |
| PCT Publication Date: | December 15, 2016 | PCT Publication Number: | WO2016/201227 |
International Family Members for US Patent 11,234,976
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2016276951 | ⤷ Sign Up | |||
| Australia | 2021200060 | ⤷ Sign Up | |||
| Canada | 2989111 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
